# Ironwood Pharmaceuticals, Inc. clinical trials: 25 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 25 trials with Ironwood Pharmaceuticals, Inc. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Ironwood Pharmaceuticals, Inc.: 25 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/ironwood-pharmaceuticals-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 25
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 25, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| February 22, 2023 | NCT05740007 | A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome | Ironwood Pharmaceuticals, Inc. | Phase 2 | Terminated | Interstitial Cystitis, Bladder Pain Syndrome | 98 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05740007) |
| May 5, 2022 | NCT05362695 | A Study of Multiple-ascending Doses of IW-3300 in Healthy Subjects | Ironwood Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteers | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05362695) |
| January 12, 2022 | NCT05188261 | A Study of Single Ascending Doses of IW-3300 in Healthy Volunteers | Ironwood Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteers | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05188261) |
| April 30, 2019 | NCT03931785 | A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome | Ironwood Pharmaceuticals, Inc. | Phase 2 | Completed | Irritable Bowel Syndrome With Diarrhea (IBS-D) | 515 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03931785) |
| February 27, 2019 | NCT03856970 | Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy... | Ironwood Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteers | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03856970) |
| June 29, 2018 | NCT03573908 | A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) | Ironwood Pharmaceuticals, Inc. | Phase 3 | Completed | Irritable Bowel Syndrome Characterized by Constipation | 614 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03573908) |
| June 19, 2018 | NCT03561883 | Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs) | Ironwood Pharmaceuticals, Inc. | Phase 3 | Completed | Gastroesophageal Reflux Disease (GERD) | 609 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03561883) |
| June 19, 2018 | NCT03561090 | A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs) | Ironwood Pharmaceuticals, Inc. | Phase 3 | Terminated | Gastroesophageal Reflux Disease (GERD) | 495 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03561090) |
| July 24, 2017 | NCT03226899 | A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment | Ironwood Pharmaceuticals, Inc. | Phase 4 | Terminated | Gout, Chronic Kidney Disease (CKD) | 242 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03226899) |
| July 20, 2016 | NCT02837783 | A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C) | Ironwood Pharmaceuticals, Inc. | Phase 4 | Terminated | Irritable Bowel Syndrome Characterized by Constipation | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02837783) |
| December 22, 2015 | NCT02637557 | A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD) | Ironwood Pharmaceuticals, Inc. | Phase 2 | Completed | Gastroesophageal Reflux Disease | 282 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02637557) |
| September 24, 2015 | NCT02559206 | Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) | Ironwood Pharmaceuticals, Inc. | Phase 2 | Completed | Irritable Bowel Syndrome With Constipation | 759 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02559206) |
| November 14, 2014 | NCT02291679 | Trial of Linaclotide in Patients With Chronic Idiopathic Constipation | Ironwood Pharmaceuticals, Inc. | Phase 3 | Completed | Chronic Idiopathic Constipation | 1,223 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02291679) |
| November 13, 2014 | NCT02289846 | Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP) | Ironwood Pharmaceuticals, Inc. | Phase 2 | Completed | Diabetic Gastroparesis | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02289846) |
| January 9, 2014 | NCT02030925 | Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors | Ironwood Pharmaceuticals, Inc. | Phase 2 | Completed | Gastroesophageal Reflux | 93 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02030925) |
| October 23, 2012 | NCT01712412 | Phase 2a Study of IW-9179 to Treat Functional Dyspepsia | Ironwood Pharmaceuticals, Inc. | Phase 2 | Terminated | Dyspepsia, Functional Gastrointestinal Disorders | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01712412) |
| April 20, 2010 | NCT01107236 | Study to Evaluate Efficacy and Safety of IW-6118 in Patients Undergoing Third Molar Extraction | Ironwood Pharmaceuticals, Inc. | Phase 2 | Completed | Healthy | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01107236) |
| July 14, 2009 | NCT00938717 | Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) | Ironwood Pharmaceuticals, Inc. | Phase 3 | Completed | Irritable Bowel Syndrome With Constipation | 805 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00938717) |
| August 8, 2008 | NCT00730171 | An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation | Ironwood Pharmaceuticals, Inc. | Phase 3 | Completed | Irritable Bowel Syndrome With Constipation, Chronic Constipation | 1,743 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00730171) |
| August 8, 2008 | NCT00730015 | Trial of Linaclotide in Patients With Chronic Constipation | Ironwood Pharmaceuticals, Inc. | Phase 3 | Completed | Chronic Constipation | 643 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00730015) |
| April 16, 2007 | NCT00460811 | Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With... | Ironwood Pharmaceuticals, Inc. | Phase 2 | Completed | Irritable Bowel Syndrome With Constipation | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00460811) |
| November 27, 2006 | NCT00404001 | Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia | Ironwood Pharmaceuticals, Inc. | Phase 2 | Completed | Hypercholesterolemia | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00404001) |
| November 22, 2006 | NCT00402337 | Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation | Ironwood Pharmaceuticals, Inc. | Phase 2 | Completed | Chronic Constipation | 310 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00402337) |
| March 24, 2006 | NCT00306748 | Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic Constipation | Ironwood Pharmaceuticals, Inc. | Phase 2 | Completed | Constipation | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00306748) |
| November 24, 2005 | NCT00258193 | Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS | Ironwood Pharmaceuticals, Inc. | Phase 2 | Completed | Irritable Bowel Syndrome | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00258193) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 3 |
| Phase 2 | 13 |
| Phase 3 | 7 |
| Phase 4 | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 20 |
| Terminated | 5 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Gastroesophageal Reflux | 4 |
| Irritable Bowel Syndrome | 3 |
| Constipation | 2 |
| Hypercholesterolemia | 1 |
| Hyperlipidemias | 1 |
| Dyslipidemias | 1 |
| Gout | 1 |
| Renal Insufficiency, Chronic | 1 |
| Abdominal Pain | 1 |
| Diarrhea | 1 |
| Cystitis, Interstitial | 1 |
| Dyspepsia | 1 |
| Gastrointestinal Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Hazardous waste disposal companies in the United States](https://specstream.ai/data/businesses/hazardous-waste-disposal-companies/united-states)
- [Indo Chinese restaurants in the United States](https://specstream.ai/data/businesses/indo-chinese-restaurants/united-states)
- [Land surveyors in the United States](https://specstream.ai/data/businesses/land-surveyors/united-states)
- [Medical law firms in the United States](https://specstream.ai/data/businesses/medical-law-firms/united-states)
- [Occupational medicine clinics in the United States](https://specstream.ai/data/businesses/occupational-medicine-clinics/united-states)
